Syngen Biotech Co.,Ltd. (TPEX:8279)

Taiwan · Delayed Price · Currency is TWD

78.00

-0.70 (-0.89%)

Sep 30, 2026, 1:30 PM CST

Market Cap	2.13B -36.8%
Revenue (ttm)	2.05B -3.3%
Net Income	226.03M -19.1%
EPS	8.33 -19.0%
Shares Out	27.10M
PE Ratio	9.45
Forward PE	n/a
Dividend	5.00 (6.41%)
Ex-Dividend Date	Jun 25, 2026

Volume	10,202
Open	78.80
Previous Close	78.70
Day's Range	78.00 - 78.80
52-Week Range	77.60 - 141.00
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, and capsules; and elderly health care, beauty enhancing supplements, probiotics, digestive aids and enzymes, weight loss and nutrition... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1988

Employees 247

Stock Exchange Taipei Exchange

Ticker Symbol 8279

Full Company Profile

Financial Performance

In 2025, Syngen Biotech's revenue was 2.14 billion, an increase of 6.10% compared to the previous year's 2.01 billion. Earnings were 271.59 million, an increase of 13.07%.

Financial Statements